PEPG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
PepGen Inc. is not a good buy for a beginner, long-term investor at this time. The stock is under significant pressure due to negative news catalysts, poor financial performance, and bearish technical indicators. While insider buying and analyst ratings suggest some potential, the risks outweigh the benefits given the investor's profile and goals.
The technical indicators for PEPG are bearish. The MACD histogram is negative and contracting, the RSI indicates the stock is oversold at 17.099, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with a pivot at 1.71 and the next support at 1.595.
Insiders are buying, with a significant increase of 294713.82% in buying activity over the last month. Analysts have issued Buy ratings with price targets significantly above the current price, indicating potential upside.
The FDA has placed a partial hold on the PGN-EDODM1 clinical trial, and there are concerns about kidney safety risks. The stock has experienced sharp declines due to negative news and poor clinical data. Additionally, Pomerantz LLP is investigating the company for potential securities fraud.
PepGen's financials for 2025/Q4 show no revenue growth (0% YoY), a net income drop of -17.54% YoY to -$18.34M, and a significant EPS decline of -60.29% YoY to -0.27. The company is not generating any revenue and is incurring heavy losses.
Analysts have issued Buy ratings with price targets of $7 and $15, citing potential best-in-class efficacy for DM1. However, concerns about kidney safety and lackluster clinical data weigh heavily on the stock's outlook.
